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A B S T R A C T   
Blood levels of cardiac troponins (cTn) and myoglobin are analysed when myocardial infarction (MI) is sus-
pected. Here we describe a novel clearance mechanism for muscle proteins by muscle cells. The complete plasma 
clearance profile of cTn and myoglobin was followed in rats after intravenous or intermuscular injections and 
analysed by PET and fluorescence microscopy of muscle biopsies and muscle cells. Compared with intravenous 
injections, only 5 % of cTnT, 0.6 % of cTnI and 8 % of myoglobin were recovered in the circulation following 
intramuscular injection. In contrast, 47 % of the renal filtration marker FITC-sinistrin and 81 % of cTn fragments 
from MI-patients were recovered after intramuscular injection. In addition, PET and biopsy analysis revealed that 
cTn was taken up by the quadriceps muscle and both cTn and myoglobin were endocytosed by cultured muscle 
cells. This local clearance mechanism could possibly be the dominant clearance mechanism for cTn, myoglobin 
and other muscle damage biomarkers released by muscle cells.   
1. Introduction 
Cardiac troponins (cTn), troponin T (cTnT) and troponin I (cTnI), are 
cardiac-specific proteins that bind to thin filaments within the car-
diomyocyte sarcomere and cooperate with troponin C (TnC) to make 
muscular contraction dependent on calcium (Filatov et al., 1999). cTnT 
and cTnI are released into the circulation following cardiac damage 
(Starnberg et al., 2014) and are now the preferred diagnostic biomarkers 
when myocardial infarction (MI) is suspected (Thygesen et al., 2019). 
Diagnosing a chest pain patient as having MI often relies on the 
patients’ cTn levels. If the cTn level is elevated, further testing is needed 
to examine whether the elevation is stable or dynamic (Bjurman et al., 
2017). Stable cTn levels are often used to exclude MI since it is thought 
that stable cTn elevations are not due to acute cardiac damage 
(Chapman et al., 2018, 2017b; Sandoval et al., 2017). 
Over a third of older patients in emergency departments have stable 
cTn elevations without an obvious connection to MI or other cardiac 
damage (Hammarsten et al., 2012; Shah et al., 2018). These patients 
constitute a significant health care problem since stable elevation of cTn 
is one of the strongest known risk factors for death and heart disease 
(Carlsson et al., 2017; Chapman et al., 2017a; Roos et al., 2017a). 
After MI has been excluded, patients with stable cTn elevations are 
often left with information of future risks but without treatment (Roos 
et al., 2017b), as we still do not understand the pathophysiological 
mechanisms that link stable cTn elevations to mortality (Hammarsten 
et al., 2018). 
One possibility is that a stable cTn elevation is due to decreased 
clearance (Friden et al., 2017). Surprisingly, little is known about how 
cTn, myoglobin and other muscle damage biomarkers are cleared from 
the circulation. cTn and myoglobin are cleared, in part, by the kidneys 
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(Friden et al., 2017), and are often elevated in patients with low kidney 
function (Bjurman et al., 2015; Hallgren et al., 1978; Wodzig et al., 
1997; Ziebig et al., 2003). However, circumstantial evidence suggests 
that other clearance systems, like receptor-mediated endocytosis and 
degradation in the liver (Muslimovic et al., 2020), are involved (Friden 
et al., 2017; Smit et al., 1988, 1987). 
During our studies of cTn clearance we found that very little cTn and 
other muscle proteins emerged in the circulation after injection into the 
rat quadriceps muscle. Here, we have examined the local clearance of 
cTn and myoglobin in muscles in greater detail. 
2. Material and methods 
2.1. Animals 
Male Sprague Dawley rats (Taconic, Denmark) kept on standard 
fodder and with free access to water, were used, unless otherwise stated. 
Anesthesia was induced and maintained by inhalation of isoflurane 
(Isobavet, Schering-Plough Animal Health, Buckinghamshire, UK; 4.5 % 
induction and 3.2–3.9 % maintenance), using the Univentor 400 anes-
thesia unit (AgnTho’s AB, Lidingö, Sweden). 
2.2. Ethical standards 
All protocols and procedures involving animal experiments were in 
accordance with the guidelines in Directive 2010/63/EU of the Euro-
pean Parliament and of the Council on the protection of animals used for 
scientific purposes and approved by the Regional Board for Ethical Re-
view of research projects using animals in Gothenburg, appointed by the 
Swedish Ministry of Agriculture, (Ethical Approval # 282-2012). 
2.3. Cell maintenance 
Mouse muscle C2C12 cells (ATCC) were cultured in a Dulbecco’s 
Modified Eagle’s Medium (DMEM) with High Glucose (Thermo Fisher 
Scientific) supplemented with 10 % fetal bovine serum or 10 % horse 
serum, 1 % penicillin/streptomycin. The cells were detached with 
trypsin-EDTA 0.25 % for five minutes and passaged twice a week. For 
confocal microscopy imaging, the cells were plated on 8-well chamber 
slides (ibi-treat 8-well μ-slides from ibidi, LRI instruments Inc.) with 5.0 
× 103 viable cells/cm2 and cultured for 5− 10 days prior to the experi-
ment with medium change twice a week. 
2.4. Preparation of cardiac extract 
Serum extract of rat cardiac tissue: Frozen small pieces of rat cardiac 
tissue free from connective tissue and fat were homogenized in a 1:2 vol 
ratio in rat serum using a glass Dounce homogenizer at room tempera-
ture. The resulting homogenate was centrifuged at 10 000 RFC for 30 
min. The clear supernatant was supplemented with 10 μl/mL sterile 0.2 
M CoCl3 0.4 M EDTA solution before being filtered through a 2 μm filter 
(Millex®GS) and stored at − 20 ◦C. The cardiac troponin T (cTnT) con-
centration was 1.53–4.9 mg/L in different extracts, as measured by the 
Roche hs-cTnT assay. 
2.5. Purification of a cTn complex from pig heart 
The cTn complex was prepared essentially as described, using 700 g 
of frozen left ventricular cardiac pig tissue or 8 g of rat left ventricular 
cardiac tissue. The method below pertains to the cTn preparation of left 
ventricular cardiac pig tissue that was used in the animal experiments. 
The clearance kinetics of rat cTn and pig cTn were similar after an 
intravenous (i.v.) injection, data not shown. The diethyl ether powder 
was extracted twice, for 1 h at a time, with 400 mL phosphate-buffered 
saline, PBS complemented with 1 M NaCl, 1 mM CaCl2 and 1 mM 
Dithiothreitol, DTT and protease inhibitors (1x cOmplete™, EDTA-free 
Protease Inhibitor Cocktail (Roche). The extract was fractionated by 
ammonium sulphate precipitation as described. The 43.5 % ammonium 
sulphate pellet was dissolved in a total of 110 mL of Buffer P (0.1 M Tris- 
HCl pH 7.5, 0.1 M NaCl, 0.1 m M CaCl2), cleared by centrifugation and 
loaded on a 10 mL MMC column (GE Health Care) equilibrated with 
Buffer P1, washed with 5 column volumes of PBS supplemented with 1 
M NaCl, followed by 5 column volumes of MQ water and finally 
developed with a 100 mL gradient using 50 mL 1 M NaCl, 0.1 M NaOH, 
collecting 2 mL fractions. The fractions were rapidly supplemented with 
200 μL Tris-HCl, pH 7.5, 1 mM DTT to normalize the pH level, and stored 
at − 20 ◦C. The final yield from 700 g heart tissue was 23 mg cTn, 
measured with the Bicinchoninic Acid Kit for Protein Determination 
(Sigma) with bovine serum albumin as standard. The presence of cTnT 
and cTnI was confirmed using the Abbott STAT high-sensitivity cTnI 
assay and the Roche high-sensitivity cTnT assay. The presence of 
troponin C was inferred from overloaded SDS gels (Supplementary Fig. 
1), but not directly detected or measured. The undiluted peak fractions 
with a protein concentration of 2 mg/mL had a tendency to precipitate 
at low ionic strength. For that reason, the cTn fractions were stored and 
labeled with NHS Alexa dye in buffers containing 1 M NaCl, as described 
in the next section. Prior to injection in the animals, the cTn prepara-
tions were diluted to 100-fold lower concentrations (< 0.1 mg/mL, see 
below) and centrifuged at 13 000 G for 5 min to remove any precipitate. 
However, at these lower concentrations, both the Alexa-labeled and 
unlabeled cTn preparations remained in solution with no evidence of 
precipitation. 
2.6. Enrichment of cTnT fragments from patients with myocardial 
infarction 
Serum samples were pooled from 50 patients with myocardial 
infarction and diluted twofold with 2 M NaCl to reach a final concen-
tration of 1 M NaCl. The diluted serum was centrifuged for 10 min at 14 
000 rpm and then filtered through a 0.22 μm filter before it was loaded 
on a Biorad 40 mL open column packed with 10 mL of Capto MMC resin 
(GE Healthcare), equilibrated with 150 mmol/L KPO4, pH 7.0. The 10 
mL Capto MMC resin was washed with 50 mL 1 M NaCl, 1 mM CaCl2 and 
eluted in 1 mL fractions with 100 mmol/L NaOH with the addition of 
EDTA-free Protease Inhibitor Cocktail (Roche) in plastic tubes prefilled 
with 200 μL of KPO4 pH 4.5, to normalize pH to 7.0 quickly. The peak 
cTnT activity measured with the Roche high-sensitivity cTnT assay was 
found in fraction 8–12 and was pooled. The final preparation had cTnT 
levels of 4900 ng/L and were composed of cTnT degradation products 
with a molecular weight < 20 kDa, according to SDS-PAGE analysis, as 
previously described. 
2.7. Labeling of proteins with Alexa-N-hydroxysuccinimide (Alexa-NHS) 
Pig cTn preparations, horse myoglobin (Myo) and pig lactate dehy-
drogenase (LDH) (Sigma) were desalted on a G50 column in Buffer L (0.2 
M NaCO3 pH 8.3, 1 M NaCl) to remove all possible traces of Tris or other 
amine contaminants that otherwise could interfere with the N-hydrox-
ysuccinimide (NHS) labeling. The proteins were concentrated on ultra-
centrifugation columns (Amicon) with the exclusion limit of 3 K to a 
protein concentration of 5− 10 g/L. If lower protein concentrations were 
used, labeling with the NHS-Alexa reagents was inefficient. Alexa-NHS 
488, Alexa-NHS 305 or Alexa-NHS 700 (Thermo Fisher Scientific) 
were added in fivefold molar excess and allowed to react in Buffer L for 
3− 24 h at room temperature. The reaction mixture was then supple-
mented with an equal volume of 2 M Tris-HCl pH 7.5 to inactivate the 
NHS group, and purified away from the unreacted Alexa dye on a G50 
column in Buffer L. High molecular weight peak fractions containing the 
labeled proteins were concentrated on ultracentrifugation columns 
(Amicon) with the exclusion limit of 3 K and stored at − 20 ◦C. The molar 
ratio of Alexa label to protein was 1–3 molecules per protein. When 
higher levels of labeling were used, the Alexa-labeled cTn preparations 
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had a tendency to precipitate. 
2.8. Intramuscular injection of ground rat cardiac tissue 
The rats were anesthetized and a reference blood sample (150 μL) 
was collected by tail snip. A tissue adhesive (Histoacryl®, B. Braun, 
Germany) was used for wound closure. Intramuscular injections were 
performed in the quadriceps muscle, located on the cranial aspect of the 
femur. Two rats were injected with 75 μL of ground rat cardiac tissue 
and one rat was injected with physiological saline (0.9 % NaCl). The 
weight of the syringe was measured before and after injections in order 
to quantify the exact amount of injected substance. Blood samples (150 
μL) were collected via the tail vein in conscious animals 1 h, 3 h, 6 h, and 
24 h post injection. Whole blood samples were left to stand for 60 min at 
room temperature prior to centrifugation (Heraeus Fresco 17, Thermo 
Scientific GmbH, Germany) at 9600 rcf for 10 min at 4 ◦C. Serum was 
removed from the red blood cells and stored at − 20 ◦C. 
2.9. Intravenous and intramuscular injection of cardiac extract and 
biomarkers 
The rats were anesthetized and reference blood samples (150 μL) 
were collected from all rats by tail snip, and a tissue adhesive (Histo-
acryl®, B. Braun, Germany) was applied for wound closure. The intra-
venous injections of 200 μL of cardiac extract or biomarkers including 
purified cTn complex, FITC-Dextran and FITC-Sinestrin were adminis-
tered via the tail vein in three rats, while another group of three rats was 
given intramuscular injections of 100 μL of the cardiac extract or bio-
markers administered in the biceps femoris (hind limb). Blood samples 
(150 μL) were collected via the tail vein in conscious animals 5 min, 10 
min, 30 min, 60 min, 90 min, 3 h, 6 h and 24 h after the injection. The 
maximum measured cTnT activity during the experiments described 
below was 10 000–12 000 ng/L, 19 000–22 000 ng/L for cTnI and 40–90 
u g/L for Myo. As the analysis of cTnT and cTnI was performed with 
clinical assays calibrated using human cTnT or cTnI, the relative con-
centration was calculated where the highest measured concentration in 
each rat was set to 100. Whole blood samples were left to stand for 60 
min at room temperature prior to centrifugation (Heraeus Fresco 17, 
Thermo Scientific GmbH, Germany) at 9600 RCF for 10 min at 4 ◦C. 
Serum was removed from the red blood cells and stored at − 20 ◦C. 
2.10. Intramuscular injection of cTn and histology 
Pig cTn was fluorescently labeled with Alexa 488 and injected in to 
the left quadriceps muscle in rats. Muscle biopsies were collected after 
30 min or 24 h and fresh frozen using isopentane chilled in liquid ni-
trogen. The frozen tissue was sectioned using a cryotome into 7 μm 
sections. For analysis of histology sections were stained with 
Hematoxylin-Eosin. The frozen tissue sections were fixed in − 20 ◦C 
acetone for 10 min, washed in Phosphate Buffer Saline (PBS) and 
mounted with prolong gold antifade reagent with DAPI (Invitrogen). 
The results were visualized using an ECLIPSE Ti microscope (Nikon 
Corporation, Tokyo, Japan) using brightfield microscopy for histology 
and fluorescence for analyses of the cTn content. Images were acquired 
at 3 Z-levels to capture all the nuclei in focus. For brightfield images 
Nikon DS-2 Mv camera was used. Fluorescence images were acquired for 
two channels; DAPI and FITC using an Andor Zyla camera. All images 
were exported to Image J software (v. 1.47 h, Fiji distribution) (Schin-
delin et al., 2012) for further analysis. For each channel, displayed pixel 
ranges were set so that most of the background was extinguished. The 
composite photos were used for analyses of the content of Alexa 488-cTn 
in large areas, provided by the photos. 
2.11. PET analysis of i.v. 18F-cTn injections in rat 
Pig cTn (2 mg/mL) was labeled with 18F for PET-imaging by using a 
similar approach as described by Olberg et al. (Olberg et al., 2010). 
18F-cTn was then purified on a PD MidiTrap G-10 gravity column (GE 
Healthcare Bio-Sciences) using saline as eluent. The integrity of 18F-cTn 
was confirmed by size-exclusion chromatography using a TSKgel 
G2000SWXL column (Tosoh Bioscience LLC) and a Thermo Scientific 
UltiMate 3000 Rapid Separation system. The elution pattern of 18F-cTn, 
as detected by an inline 35 μL gamma D flow cell and a Radiomatic 
625TR Flow Scintillation Analyzer (PerkinElmer Inc.), was similar as 
unlabeled cTn complex as detected by the UltiMate™ 3000 Diode Array 
Detector Flow Cell (2.5 μm). 30 min dynamic PET scan (small-animal 
PET/CT, NanoScan PC PET/CT; Mediso Ltd, Budapest, Hungary) was 
obtained during sevoflurane anesthesia after bolus injection of 1 mL 
saline containing 5–8 MbQ 18 F-cTn in into a lateral tail vein. The rat 
was then allowed to wake up and a final 5 min static PET-scan was 
performed under sevoflurane anesthesia about 3 h after tracer injection. 
PET scan acquisitions parameters were as follows: Field of view 9.6 cm 
in the axial direction and 10 cm in the transaxial direction, 1:5 coinci-
dence mode and normal count rate mode. The body temperature was 
maintained at 37 degrees throughout the whole procedure. Recon-
struction of the PET data was performed with 3D OSEM and 1:5 coin-
cidence mode, no filtering, attenuation correction (from a helical 
CT-scan, 50 kVp, 300 ms, 360 projections reconstructed using 
Ram-Lak filter), decay correction and normalization of detectors. The 
images were analysed using Interview fusion software (version 
3.01.021.0000)”. 
2.12. Endocytosis experiments and confocal microscopy 
Mouse muscle C2C12 cells were washed twice with 37 ◦C preheated 
serum-free medium and incubated at 37 ◦C for 30 min prior to protein 
addition. The proteins Alexa488-cTn (4.6ug/L), Alexa488-transferrin 
(0.1 g/L), Alexa488-myoglobin (1.3ug/L), and Alexa488-BSA (1.7ug/ 
L) were diluted in 37 ◦C preheated medium and added to the cells for 2 h 
at 37 ◦C. The endocytosis inhibitor Dynasore hydrate (Sigmaaldrich) (50 
μM) was added to the cells 30 min before addition of the proteins. As 
recommended, Dynasore hydrate treatment was performed in DMEM, 
High-Glucose without serum. Following incubation, the cells were 
washed twice with PBS, fixed with 4 % paraformaldehyde (PFA) in PBS 
for 15 min at room temperature and washed once again with PBS. The 
nuclei were stained with 1 μM NucBlue Live ReadyProbes Reagent 
containing Hoechts 33342 (Thermo Fisher Scientific) in PBS for 5 min, 
washed 1X with PBS and 2X with MQ water, and mounted with ibidi 
mounting medium (LRI Instruments Inc.). Confocal imaging was per-
formed on a Nikon Eclipse Ti confocal microscope using a Nikon Apo 
20X and Apo 60 × 1.40 oil immersion objective with 405 nm and 488 
nm lasers for Hoecht 33342 and Alexa Fluor 488, respectively, and 
fluorescence was detected using filter/bandpass of 450 nm/50 nm and 
525 nm/50 nm for the blue and green channel, respectively. All images 
were exported to Image J software (v. 1.47 h, Fiji distribution) (Schin-
delin et al., 2012) for further analysis. 
2.13. Laboratory analyses 
Serum samples were stored at − 20 ◦C before dilution in PBS sup-
plemented with 1 g/L bovine serum albumin and analysis at the Clinical 
Chemistry Laboratory at Sahlgrenska University Hospital. Analysis of 
cTnT was performed using the latest versions of Roche hs-cTnT method 
on Cobas (Hammarsten et al., 2013). Analysis of cTnI was performed 
using the latest versions of the Abbott hs-cTnI method on Architect. All 
methods had a CV < 5 % within the range measured in the study. 
The Abbott hs-cTnI method is specific for cardiac cTnI and does not 
cross-react with skeletal muscle proteins. The Roche hs-cTnT method 
cross-reacts with something in skeletal muscle and extensive skeletal 
muscle damage or myositis is known to generate cTnT elevations in 
patients (Schmid et al., 2018). However, the amount of cTnT measured 
in skeletal muscle extracts are several orders of magnitude lower 
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compared to cardiac muscle extracts from humans (Schmid et al., 2018) 
and rats (Hammarsten, unpublished observations) and this possible 
interference is likely of no significance in our studies. 
Myoglobin was measured using a high-sensitive rat Myoglobin ELISA 
with a CV of 14.9 % at 13.5 ug/L (LIFE diagnostics) The same form of 
myoglobin is expressed in both skeletal and cardiac muscle and we can 
therefore not exclude that myoglobin released after i.m. injection 
interfered with our measurements. 
2.14. Statistical analysis 
The statistical significance was tested using the two-sided non-paired 
t-test using Excel 2011. P values < 0.05 were considered significant. 
3. Results 
3.1. Clearance following tail vein or quadriceps muscle injection 
We followed the serum concentration for 24 h following a tail vein 
injection (i.v.) or injection into the left quadriceps muscle (i.m.) in rats 
(Fig. 1). Almost 50 % of the renal filtration marker FITC-sinistrin, not 
expected to be taken up by muscle cells and with a free passage over the 
muscular capillaries, was recovered in the circulation after an i.m. in-
jection. In contrast, less than 10 % of FITC-dextran, known to be taken 
up through endocytosis by muscle cells (Lawoko and Tagerud, 1995), 
was recovered after an i.m. injection (Fig. 2). We then compared the 
recovery of cTnT, cTnI and myoglobin after i.v. or i.m. injections. We 
decided to use cardiac troponins and not skeletal muscle troponins, as 
we have excellent clinical assays for cardiac troponins capable of 
measuring also small degradation products (Friden et al., 2017; Streng 
et al., 2017) in plasma samples. The source of the cTnT, cTnI and 
myoglobin was either plasma extract of in vitro crushed rat cardiac tissue 
to simulate the cTnT, cTnI and myoglobin release following muscle 
damage (Fig. 3), or a purified pig cTn complex (Fig. 4) (Supplemental 
Fig. 1). Only small amounts of the cTnT and cTnI injected by the i.m. 
route reached the circulation during 24 h (Table 1). Myoglobin, a small 
protein (17 kDa) with expected free passage over muscular capillaries 
(Sarin, 2010) also seemed to be catabolized by the muscular tissue 
(Table 1) (Fig. 5A) Supplementary Figs. 5–9). In contrast, over 80 % of 
serum cTnT fragments enriched from patients with myocardial infarc-
tion (Friden et al., 2017) was recovered in the circulation after i.m. in-
jection in one rat (Fig. 5B, Table 1, Supplementary Fig. 10). 
3.2. Fluorescence microscopic examination after intramuscular injection 
of cTn 
To examine if cTn was retained in muscle cells after an i.m. injection, 
fluorescently labeled pig cTn was injected into the left quadriceps 
muscle in rats (Fig. 6). Muscle biopsies were collected after 30 min or 
after 24 h, flash frozen and examined by fluorescence microscopy. 
Within 30 min of injection, essentially all of the fluorescence signal was 
found within the myocytes. Green fluorescence was still detected but 
with weaker intensity in the injection area after 24 h. 
3.3. PET analysis of cTn after intramuscular injection 
PET analysis of 18F-labeled cTn revealed that most 18F-activity 
accumulated in the liver and kidneys after an i.v. injection (Fig. 7A). In 
contrast, after an i.m. injection, most of the 18F-activity remained in the 
quadriceps muscle during the first 30 min and was then lost in the urine 
during the following three hours (Fig. 7B). Some of the 18F-activity was 
found in a local point-like structure, most likely a lymph gland (Sup-
plemental Fig. 2). Very small amounts of 18F -activity were found in the 
liver or spleen after an i.m. injection as opposed to after an i.v. injection, 
indicating that most of the 18F-activity that escaped from the muscle 
were degradation products or free 18F that was cleared by the kidneys. 
3.4. Endocytosis of cTn by myotubes 
Mouse C2C12 myotubes (Supplemental Fig. 3) internalized fluo-
rescently labeled cTn, myoglobin and transferrin (Fig. 8A) that was 
Fig. 1. Outline of the experimental system. Rats were injected with different 
preparations in pairs through the tail vein (i.v.) or into the quadriceps muscle (i. 
m.), and the clearance of cTnT, cTnI and other molecules was followed by blood 
sampling or by positron emission tomography (PET) analysis. 
Fig. 2. Kinetics of FITC-sinestrin (1 kDa) (A) or FITC-Dextran (40 kDa) (B) 
clearance following an i.v. (black line) or i.m. (red line) injection. Mean values 
from three rats. Error bars represent ± 1SD. 
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blocked by the endocytosis inhibitor Dynasore (Fig. 8B). No appreciable 
internalization of fluorescently labeled bovine serum albumin was 
observed (Supplemental Fig. 4). This indicates that myocytes are able to 
take up cTn and Myoglobin, likely by endocytosis. 
4. Discussion 
We show by using cardiac troponins and myoglobin that muscle 
proteins are cleared by muscle tissue. The system prevented over 90 % of 
the injected cTn and myoglobin from reaching the circulation and could 
therefore be the dominant clearance mechanism for released cTn and 
myoglobin. Thus, a troponin or a myoglobin molecule in between rat 
skeletal muscle cells is unlikely to reach the circulation despite 
myoglobin having free passage over muscular capillaries (Sarin, 2010). 
The retention of cTn after i.m. injection was similar when we used pu-
rified cTn and serum extract of cardiac tissue. Therefore, the local 
clearance of cTn was not inhibited by serum proteins and therefore 
displayed some form of specificity. 
We used clinical immunoassays capable of measuring degradation 
products of cTnT, cTnI and myoglobin, making it unlikely that degra-
dation between cells was the only reason for poor recovery in the cir-
culation after i.m. injection. 
Fluorescently labeled cTn was rapidly taken up by skeletal muscle 
after an i.m. injection. This is in contrast to albumin that only occupies 
the interstitial space between muscle cells shown by injection of the 
albumin-specific (Huggins et al., 1963) dye Evans blue (Hamer et al., 
2002). 
Long term retention of 18F labeled cTn after i.m. injection was also 
observed by PET analysis. Very little of the 18F activity, was recovered in 
the rat liver or spleen in the PET analysis after an i.m. injection, indi-
cating that cTn was catabolized locally in the muscle tissue, possibly in 
the lysosomes after uptake via endocytosis. The possibility that local 
Fig. 3. Kinetics of cTnT and cTnI clearance following an i.v. (black line) or i.m. 
(red line) injection of rat cardiac serum extract. Mean values from three rats. 
Error bars represent ± 1SD. 
Fig. 4. Kinetics of cTnT and cTnI clearance following an i.v. (black line) or i.m. 
(red line) injection of partially purified cardiac troponin complex from pig 
heart. Mean values from three rats. Error bars represent ± 1SD. 
Source: Reproduced with permission from SciRep, http://creativecommons. 
org/licenses/by/4.0/. 
Table 1 
Comparison of recovery in blood samples after i.v. or i.m. injection.  
Substance measured in 
blood samples at different 
times after i.v. or i.m. 
injection 
Area under time 
concentration curve after 
i.v. injection (reference) 
Area under time 
concentration curve after 
i.m. injection† (SEM) 
FITC-Sinestrin 100 47 (n.a.) 
FITC-Dextran 100 8.1 (1.7) 
Myoglobin (rat)* 100 7.8 (1.4) 
cTnT (rat)* 100 4.8 (1) 
cTnI (rat)* 100 0.6 (0.1) 
cTnT (pig)# 100 11.4 (2.4) 
cTnI (pig)# 100 2.4 (0.2) 
cTnT (patient serum)§ 100 81.1 (n.a.)  
† Relative area under the time-concentration curve (AUC) using the AUC after 
an i.v. injection as reference; that is, the area under the time-concentration curve 
(AUC) from an i.v. injection (black line in plots) divided by the AUC after an i.m. 
injection (red line in plots). 
* Serum extract of rat heart. 
# Pig cardiac troponin complex. 
§ cTnT activity from pooled serum samples from patients with myocardial 
infarction. 
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clearance was due to endocytosis was supported by the ability of the 
endocytosis inhibitor Dynasore to decrease myotube uptake of fluores-
cent cTn and myoglobin. 
In general, despite its obvious importance, not much is known about 
the plasma clearance of muscle damage biomarkers. Early studies indi-
cate that myoglobin is predominantly cleared in the liver after an MI 
(Hallgren et al., 1978; Roxin et al., 1979; Sylven, 1978) and rhabdo-
myolysis (Amako et al., 1963), although myoglobin is small enough to 
be cleared by the kidneys. Studies in dogs indicate that creatine kinase is 
cleared from the circulation by the reticuloendothelial system (Guzy, 
1977). Studies in rats and mice show that intracellular proteins like 
lactate dehydrogenase and creatine kinase that are too large to pass 
through the glomerular membrane are cleared by receptor-mediated 
endocytosis in the liver and the spleen (Ashwell and Harford, 1982; 
Smit et al., 1987). Although the responsible receptors were not identi-
fied, scavenger receptors are likely involved. Scavenger receptors, like 
the LDL-receptor(Schneider et al., 1982), are a loosely defined group of 
receptors that bind a vast array of ligands and often destine them for 
endocytosis and degradation in lysosomes (Prabhudas et al., 2014). 
Mice with a compromised reticuloendothelial system (Hayashi and 
Notkins, 1994; Hayashi et al., 1988) or with mutations in scavenger 
receptors (Radi et al., 2011) develop stable elevations of lactate dehy-
drogenase, creatine kinase and aspartate aminotransferase. Common 
sequence variants in scavenger receptors are linked to high serum levels 
of lactate dehydrogenase and creatine kinase in humans (Kristjansson 
et al., 2016), indicating that inefficient scavenger receptor-mediated 
clearance could contribute to stable elevations of muscle damage bio-
markers also in humans. 
Most cells, including skeletal muscle cells, express scavenger re-
ceptors that are involved in endocytosis and the uptake of various 
molecules (Ezzat et al., 2015; Miyatake et al., 2019). Indeed, it is well 
established that skeletal muscle cells have a very active 
receptor-mediated endocytosis system capable of removing dextran, 
hemoglobin (Janeczko et al., 1985) and other macromolecules from 
their surroundings (Elmquist et al., 1992; Garfield et al., 1975; Lawoko 
and Tagerud, 1995; Lawoko et al., 1992; Libelius et al., 1981; Libelius 
and Tagerud, 1984; Satkauskas et al., 2001; Tagerud and Libelius, 1985; 
Tagerud et al., 1990; Vult von Steyern et al., 1994). It is therefore 
possible that receptor-mediated endocytosis was responsible for the 
local clearance of cTn and myoglobin that we observed in rat muscular 
tissue. 
One might speculate on why this clearance system has not been 
found before. Early studies report results similar to ours following paired 
i.v. and i.m. injections of cytoplasmic proteins like creatine phospho-
kinase (Hsu and Watanabe, 1984). However, the strong clearance of 
creatine phosphokinase activity after an i.m. injection was interpreted as 
local inactivation of the enzymatic activity. The possibility that creatine 
phosphokinase was absorbed by the muscle tissue was never explored. 
Indeed, another muscle enzyme, creatine kinase, is rapidly inactivated if 
incubated in dog cardiac lymph (Clark et al., 1978). The theory that the 
poor recovery of muscle proteins in the circulation after muscle damage 
is due to local inactivation has prevailed (Clark et al., 1978) and possibly 
Fig. 5. (A) Kinetics of myoglobin clearance (A) following an i.v. (black line) or 
i.m. (red line) injection. Mean values from three rats. Error bars represent ±
1SD. (B) Clearance of cTnT following an i.v. (black line) or i.m. injection (red 
line) of enriched cTnT fragments from patients with myocardial infarction in 
one rat. 
Fig. 6. Distribution of Alexa488 fluorescence in cryosections of muscle biopsies collected 0.5 h or 24 h after an injection of Alexa488-labeled pig cTn complex in the 
quadriceps muscle in rat. “Out of injection site” is located far away from the injection site and represents the background signal of the muscle biopsy. Hematoxylin 
and eosin-stained sections are included as a reference to muscle cell morphology. 
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prevented anyone to pursue the possibility that muscle cells are capable 
of clearing proteins from their surroundings by endocytosis. The only 
report we have found that discusses this possibility is a study of 
myoglobin pharmacokinetics, indicating that most myoglobin released 
from skeletal muscle in humans is catabolized within the skeletal muscle 
itself (Hallgren et al., 1978). 
In contrast to full length cTnT, cTnT fragments prepared from plasma 
from patients with myocardial infarction were able to reach the circu-
lation after i.m. injection suggesting cTnT fragments residing in the 
circulation were able to escape local clearance. We (Friden et al., 2017; 
Starnberg et al., 2020) and others (Streng et al., 2017) have shown that 
most cTnT in patient plasma measured by our clinical assays are 
degradation products and very little full-length cTnT reside in the cir-
culation a few hours after myocardial infarction. We have also shown 
that most full-length cTnT injected i.v. is taken up by the liver, possibly 
by scavenger receptors (Muslimovic et al., 2020). One possible expla-
nation for the escape is that the cTnT degradation fragments found in 
patient plasma bind less well to scavenger receptors and therefore 
"survive" both local clearance and liver clearance and accumulate in the 
circulation. This finding points to the possibility that circulating forms of 
cell damage markers is a subset of molecules that are inefficiently 
cleared by scavenger receptors. However, this possibility can only be 
resolved by identification of the receptors involved. 
Finally, we have not been able to do intramyocardial injections to 
study possible local clearance in the heart. We do, however, find that 
cardiac cell cultures take up troponin and myoglobin, but not albumin 
(Muslimovic, unpublished observations). As endocytosis is blocked in 
cardiac cells by limited ischemia (Khaidakov et al., 2014) it is possible 
that troponin elevations in patients with events that are sknown to 
induce limited ischemia such as atrial flutter or strenuous exercise could 
be due to impaired local clearance. 
There are several limitations to this study. First, the number of ani-
mals included in each experiment were low. Second, our data is for the 
most part phenomenological. The data suggest the presence of an 
endocytosis-driven local clearance of muscle proteins between muscle 
cells, but we have not undertaken any attempts to identify putative re-
ceptors at this stage. 
In summary, we report that muscle proteins between muscle cells are 
cleared by muscle cells. 
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Fig. 7. (A) Positron emission tomography (PET) analysis of cTn distribution 
following an i.v. (A) or i.m. (B) injection of partially purified pig troponin 
complex labeled with 18F. The graphs are obtained from a dynamic 0-30 min 
PET scan showing 18F activity in blood, liver, kidney and bladder urine (A) and 
in leg muscles, bladder urine and a possible abdominal lymph node (B). PET-CT 
images: A; Maximum intensity projection (MIP) 3D volume displaying uptake in 
both kidneys, liver and bladder (See supplemental Fig. 2C for a 2D coronal view 
displaying the uptake in liver and left kidney). Both images are reconstructed 
by summing the 30 min uptake (static). The MIP image after 180 min was 
acquired by a 5 min static scan, showing most of the i.v. injected 18F activity 
had been excreted in the urine or intestines. B MIP reconstructions 30- and 190 
min after i.m. injection showing slow removal and some expansion of 18F ac-
tivity at the injection site, low uptake in kidney, but nothing in liver (30 min) 
and low overall abdominal uptake and urinary excretion (190 min) (see Sup-
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experiments were conducted in two different rats allowing to wake up from 
anesthesia and move freely in the cage between the 30 min dynamic scan and 
the 3 h static scan. 
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